Importance: Migraine with aura is known to increase the risk of cardiovascular disease (CVD). The absolute contribution of migraine with aura to CVD incidence in relation to other CVD risk factors remains unclear. Objective: To estimate the CVD incidence rate for women with migraine with aura relative to women with other major vascular risk factors. Design, Setting, and Participants: Female health professionals in the US (the Women's Health Study cohort) with lipid measurements and no CVD at baseline (1992-1995) were followed up through December 31, 2018. Exposures: Self-reported migraine with aura compared with migraine without aura or no migraine at baseline. Main Outcomes and Measures: The primary outcome was major CVD (first myocardial infarction, stroke, or CVD death). Generalized modeling procedures were used to calculate multivariable-adjusted incidence rates for major CVD events by risk factor status that included all women in the cohort. Results: The study population included 27 858 women (mean [SD] age at baseline, 54.7 [7.1] years), among whom 1435 (5.2%) had migraine with aura and 26 423 (94.8%) did not (2177 [7.8%] had migraine without aura and 24 246 [87.0%] had no migraine in the year prior to baseline). During a mean follow-up of 22.6 years (629 353 person-years), 1666 major CVD events occurred. The adjusted incidence rate of major CVD per 1000 person-years was 3.36 (95% CI, 2.72-3.99) for women with migraine with aura vs 2.11 (95% CI, 1.98-2.24) for women with migraine without aura or no migraine (P < .001). The incidence rate for women with migraine with aura was significantly higher than the adjusted incidence rate among women with obesity (2.29 [95% CI, 2.02-2.56]), high triglycerides (2.67 [95% CI, 2.38-2.95]), or low high-density lipoprotein cholesterol (2.63 [95% CI, 2.33-2.94]), but was not significantly different from the rates among those with elevated systolic blood pressure (3.78 [95% CI, 2.76-4.81]), high total cholesterol (2.85 [95% CI, 2.38-3.32]), or family history of myocardial infarction (2.71 [95% CI, 2.38-3.05]). Incidence rates among women with diabetes (5.76 [95% CI, 4.68-6.84]) or who currently smoked (4.29 [95% CI, 3.79-4.79]) were significantly higher than those with migraine with aura. The incremental increase in the incidence rate for migraine with aura ranged from 1.01 additional cases per 1000 person-years when added to obesity to 2.57 additional cases per 1000 person-years when added to diabetes. Conclusions and Relevance: In this study of female health professionals aged at least 45 years, women with migraine with aura had a higher adjusted incidence rate of CVD compared with women with migraine without aura or no migraine. The clinical importance of these findings, and whether they are generalizable beyond this study population, require further research.
Importance: Migraine with aura is known to increase the risk of cardiovascular disease (CVD). The absolute contribution of migraine with aura to CVD incidence in relation to other CVD risk factors remains unclear. Objective: To estimate the CVD incidence rate for women with migraine with aura relative to women with other major vascular risk factors. Design, Setting, and Participants: Female health professionals in the US (the Women's Health Study cohort) with lipid measurements and no CVD at baseline (1992-1995) were followed up through December 31, 2018. Exposures: Self-reported migraine with aura compared with migraine without aura or no migraine at baseline. Main Outcomes and Measures: The primary outcome was major CVD (first myocardial infarction, stroke, or CVD death). Generalized modeling procedures were used to calculate multivariable-adjusted incidence rates for major CVD events by risk factor status that included all women in the cohort. Results: The study population included 27 858 women (mean [SD] age at baseline, 54.7 [7.1] years), among whom 1435 (5.2%) had migraine with aura and 26 423 (94.8%) did not (2177 [7.8%] had migraine without aura and 24 246 [87.0%] had no migraine in the year prior to baseline). During a mean follow-up of 22.6 years (629 353 person-years), 1666 major CVD events occurred. The adjusted incidence rate of major CVD per 1000 person-years was 3.36 (95% CI, 2.72-3.99) for women with migraine with aura vs 2.11 (95% CI, 1.98-2.24) for women with migraine without aura or no migraine (P < .001). The incidence rate for women with migraine with aura was significantly higher than the adjusted incidence rate among women with obesity (2.29 [95% CI, 2.02-2.56]), high triglycerides (2.67 [95% CI, 2.38-2.95]), or low high-density lipoprotein cholesterol (2.63 [95% CI, 2.33-2.94]), but was not significantly different from the rates among those with elevated systolic blood pressure (3.78 [95% CI, 2.76-4.81]), high total cholesterol (2.85 [95% CI, 2.38-3.32]), or family history of myocardial infarction (2.71 [95% CI, 2.38-3.05]). Incidence rates among women with diabetes (5.76 [95% CI, 4.68-6.84]) or who currently smoked (4.29 [95% CI, 3.79-4.79]) were significantly higher than those with migraine with aura. The incremental increase in the incidence rate for migraine with aura ranged from 1.01 additional cases per 1000 person-years when added to obesity to 2.57 additional cases per 1000 person-years when added to diabetes. Conclusions and Relevance: In this study of female health professionals aged at least 45 years, women with migraine with aura had a higher adjusted incidence rate of CVD compared with women with migraine without aura or no migraine. The clinical importance of these findings, and whether they are generalizable beyond this study population, require further research.
Authors: João Eudes Magalhães; Isly Maria Lucena de Barros; Rodrigo Pinto Pedrosa; Pedro Augusto Sampaio Rocha-Filho Journal: Headache Date: 2018-12-05 Impact factor: 5.887
Authors: Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: Tobias Kurth; Anke C Winter; A Heather Eliassen; Rimma Dushkes; Kenneth J Mukamal; Eric B Rimm; Walter C Willett; JoAnn E Manson; Kathryn M Rexrode Journal: BMJ Date: 2016-05-31
Authors: Bendik S Winsvold; Francesco Bettella; Aree Witoelar; Verneri Anttila; Padhraig Gormley; Tobias Kurth; Gisela M Terwindt; Tobias M Freilinger; Oleksander Frei; Alexey Shadrin; Yunpeng Wang; Anders M Dale; Arn M J M van den Maagdenberg; Daniel I Chasman; Dale R Nyholt; Aarno Palotie; Ole A Andreassen; John-Anker Zwart Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240
Authors: Sheila E Francis; Jason Berwick; Osman Shabir; Ben Pendry; Llywelyn Lee; Beth Eyre; Paul S Sharp; Monica A Rebollar; David Drew; Clare Howarth; Paul R Heath; Stephen B Wharton Journal: Elife Date: 2022-01-11 Impact factor: 8.140
Authors: Timothy R Smith; Egilius L H Spierings; Roger Cady; Joe Hirman; Anders Ettrup; Vivienne Shen Journal: J Headache Pain Date: 2021-11-25 Impact factor: 7.277
Authors: Yanjun Guo; Pamela M Rist; Maria Sabater-Lleal; Paul de Vries; Nicholas Smith; Paul M Ridker; Tobias Kurth; Daniel I Chasman Journal: Neurology Date: 2021-04-01 Impact factor: 9.910
Authors: Eduardo Rivera-Mancilla; Linda Al-Hassany; Carlos M Villalón; Antoinette MaassenVanDenBrink Journal: Front Neurol Date: 2021-06-09 Impact factor: 4.003
Authors: David W Dodick; Anand S Shewale; Richard B Lipton; Seth J Baum; Steven C Marcus; Stephen D Silberstein; Jelena M Pavlovic; Nathan L Bennett; William B Young; Hema N Viswanathan; Jalpa A Doshi; Howard Weintraub Journal: J Prim Care Community Health Date: 2020 Jan-Dec